Corbus Pharmaceuticals Highlights Data From Its First US-Based Trial Of Lead Cancer Drug Candidate
Corbus Pharmaceuticals presented Phase 1 data on CRB-701 at ASCO GU, showing safety, tolerability, and responses across multiple tumor types.
RBC Capital Sticks to Its Buy Rating for Corbus Pharmaceuticals (CRBP)
In a report released on February 11, Brian Abrahams from RBC Capital maintained a Buy rating on Corbus Pharmaceuticals (CRBP – Research ...
Corbus Pharmaceuticals falls after trial data for lead asset
Corbus Pharmaceuticals (CRBP) stock drops 12% after mixed Phase 1 trial results for its lead cancer candidate. Read more here.
What is HC Wainwright’s Forecast for CRBP FY2029 Earnings?
Analysts at HC Wainwright issued their FY2029 earnings estimates for shares of Corbus Pharmaceuticals in a note issued to investors on Monday, February 10th. HC Wainwright analyst A. Maldonado expects ...
CRBP stock touches 52-week low at $9.1 amid market challenges
Corbus Pharmaceuticals Holdings Inc. (NASDAQ:CRBP) stock has reached a 52-week low, trading at $9.1, reflecting a period of significant pressure for the biopharmaceutical company. With a market ...
Corbus Pharmaceuticals (NASDAQ:CRBP) Given Buy Rating at HC Wainwright
HC Wainwright reaffirmed their buy rating on shares of Corbus Pharmaceuticals (NASDAQ:CRBP – Free Report) in a research ...
Corbus Pharmaceuticals (CRBP) Receives a Buy from H.C. Wainwright
In a report released on February 7, Andrew Fein from H.C. Wainwright maintained a Buy rating on Corbus Pharmaceuticals (CRBP – Research ...
Corbus Pharmaceuticals to Present at the Guggenheim SMID Cap Biotech Conference
Detailed price information for Corbus Pharmaceuticals Hldgs Inc (CRBP-Q) from The Globe and Mail including charting and trades.
Wall Street Journal14d
Corbus Pharmaceuticals Holdings Inc.
1 Day CRBP -2.32% DJIA -0.07% Russell 2K 0.00% Health Care/Life Sciences -0.02% ...